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controls for comorbid conditions—no controls, controls
for all conditions, and controls for conditions thought to
be unrelated to arthritis.
RESULTS: In the study 5920 OA and 1310 RA patients
were identified. OA patients cost between 1.50 and 2.56
times more than non-arthritis patients, while RA patients
cost between 2.21 and 3.07 times more than non-arthritis
patients. Based on assumptions about the relationships be-
tween comorbid conditions and arthritis, our point esti-
mate is that OA adds $80 per-patient-per-month (PPPM)
compared to non-arthritis patients, while RA adds $109
PPPM compared to non-arthritis patients.
CONCLUSIONS: Arthritis increases the costs of care sig-
nificantly. Existing estimation approaches either underes-
timate the cost of arthritis by including the cost of all co-
morbid conditions, or overestimate the cost by excluding
the cost of all comorbid conditions. Our approach, which
controls for only those comorbid conditions which are
unrelated to arthritis, yields a cost estimate that falls be-
tween those estimated by existing approaches and is be-
lieved to be more precise.
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OBJECTIVES: The primary aims of SCAP in Australia
are to: contribute to the establishment of a schizophrenia
outcomes database; evaluate which model of healthcare
results in better clinical outcomes and quality of life in a
naturalistic setting; and evaluate the cost of healthcare
for patients with schizophrenia. Emphasis is given to
measuring the utilization of mental healthcare services.
METHODS: SCAP is a prospective, naturalistic, non-ran-
domized 3-year follow-up study of 350 patients, with a
diagnosis of schizophrenia, schizoaffective disorder, or
schizophreniform disorder. Data on utilization of health-
care resources and costs involved in the treatment of
schizophrenia will be obtained from patient records and
from a number of state and federal databases. These cover
all healthcare services used: in hospital and out of hospi-
tal; medications and community services. The initial find-
ings based on 6-month data for the first 50 subjects were
used for a pilot study.
RESULTS: The average direct medical care cost of treating
patients over the period was calculated at A$5500. Hospi-
talizations accounted for 85% of the costs. Medications
used while the patient was in the community care ac-
counted for only 2.5% of the total costs. Ten percent of
the patients utilized over 30% of the treatment resources.
CONCLUSIONS: A full clinical costing could be under-
taken by linking data from a range of payments and activ-
ity data sets in Australia. SCAP will provide unique data
on the social and economic cost of schizophrenia. SCAP is
unique because it provides the opportunity to simulta-
neously explore a broad range of schizophrenia research
questions in a variety of settings across time. Further the
SCAP results will be drawn from a naturalistic setting and
this will enhance the generalizability of the results.
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OBJECTIVES: Alzheimer’s disease is a growing concern
due to aging of the US population and the medical re-
sources that are consumed by these patients. This study
evaluated the changes in resource utilization for newly di-
agnosed Alzheimer’s patients and a control group.
METHODS: Using an employer claims database, pa-
tients newly diagnosed with Alzheimer’s (ICD-9-CM
331.0) in 1996 (N  265) and not previously treated
with donepezil or tacrine were followed for 12 months
preceding and following diagnosis to determine medical
resource utilization. An age and gender matched control
group was constructed. Patients were 70 years of age or
older and were required to be continuously enrolled for a
24-month period.
RESULTS: Average charges per patient for the test group
were $8292 prior to diagnosis and $14,620 following
diagnosis. The control group had average charges per pa-
tient of $6199 in the pre-period and $7232 in the post
period. Charges for drugs of interest, ER visits, inpatient
hospitalizations, labs, nursing homes, outpatient services,
and other medical resources were broken down. In the
test group following diagnosis, there was a 170% in-
crease in the charge per patient for nursing home charges.
Nursing home charges for the test group following diag-
nosis accounted for 23.5% of the overall average
charges. In the control group, nursing home charges ac-
counted for only 5% of the overall average charges.
There were also increases in charges for ER visits, inpa-
tient hospitalizations, and outpatient services for the test
group following diagnosis.
CONCLUSIONS: Patients newly diagnosed with Alzhe-
imer’s consume more medical resources, mostly through
inpatient, ER, and nursing home services. Identification
of improved therapies aimed at keeping patients out of
nursing homes could produce significant cost savings.
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